A new Covid-19 pill from Merck and Ridgeback Biotherapeutics has been more widely used than expected since rolling out late last year, though regulators and many doctors consider it a last resort.
Doctors have turned to the drug, called molnupiravir, partly because a rival Pfizer pill has been in limited supply
The FDA has cleared Merck’s new Covid-19 therapy molnupiravir, the latest antiviral that adults can take at home to avoid severe disease. WSJ’s Daniela Hernandez explains the science behind the new drug. Photo: MerckA new Covid-19 pill from Merck & Co. and Ridgeback Biotherapeutics LP has been more widely used than expected sinceMany doctors and health officials anticipated a rival pill, Pfizer Inc.’s Paxlovid, would be the Covid-19 drug of choice.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Covid-19: Two Covid-related deaths and 1,669 casesThe total number of deaths linked to the virus reported by Stormont's Department of Health is 3,252.
Read more »
Covid-19: One Covid-related death and 463 in hospitalThe total number of deaths linked to the virus reported by Stormont's Department of Health is 3,253.
Read more »
Vigil marks second anniversary of COVID-19 pandemic in Sask.A small gathering took place on the steps of the Legislative Building to commemorate those lost to COVID\u002D19 in Saskatchewan.
Read more »
China Battles Nationwide Surge in Covid-19 CasesDaily infection numbers in China continued to reach levels not seen since early 2020, as health authorities rushed to stay ahead of the Omicron variant.
Read more »
San Diego organizations continue COVID-19 outreach efforts to essential workersOrganizations continue outreach efforts to educate communities on COVID-19 vaccines, paid sick leave, and testing.
Read more »
White House Warns of Blow to Covid-19 Fight as Funding StallsThe Biden administration is warning it might have to scrap critical Covid-19 programs unless Congress moves quickly to approve funding left out of the omnibus spending package
Read more »